New drug combo tested in battle against tough head & neck cancers
NCT ID NCT05814666
Summary
This study tested whether adding an experimental drug called danvatirsen to a standard immunotherapy (pembrolizumab) worked better for people with advanced head and neck cancer that had spread or come back. About 69 participants were randomly assigned to receive either the two-drug combination or the standard single drug. The main goal was to see if the combination led to more tumor shrinkage and was safe. The trial was terminated early, meaning it stopped before planned completion.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Kansas City Oncology
Merriam, Kansas, 66204, United States
-
Barts Health MHS Trust (Barts and The London NHS Trust) - St Bartholomew's (Barts) Hospital
London, EC1A 7BE, United Kingdom
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
Dong-A University Hospital
Busan, 49201, South Korea
-
East and North Hertfordshire NHS Trust, Lister Hospital
Northwood, HA6 2RN, United Kingdom
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Gyeongsang National University Hospital
Jinju, 52727, South Korea
-
Korea University Medical Center (KUMC)
Seoul, 02841, South Korea
-
Kosin University College of Medicine - Kosin University Gospel Hospital (KUGH)
Busan, 602-702, South Korea
-
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Mount Sinai
New York, New York, 10029, United States
-
Prisma Health Cancer Institute
Greenville, South Carolina, 29605, United States
-
Saint James's University Hospital (SJUH) - St James's Institute of Oncology
Leeds, United Kingdom
-
Stony Brook Cancer Center
Stony Brook, New York, 11794, United States
-
TMPN Hunt Cancer Care
Torrance, California, 90505, United States
-
The Catholic University of Korea - Eunpyeong St. Mary's Hospital
Seoul, South Korea
-
The Christ Hospital Cancer Center
Cincinnati, Ohio, 45219, United States
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
The Royal Marsden NHS Foundation Trust
Sutton, SM2 5PT, United Kingdom
-
The University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
UT Southwestern Medical Center/Simmons Comprehensive Cancer Center
Dallas, Texas, 75390, United States
-
University Hospitals Cleveland
Cleveland, Ohio, 44106, United States
-
University of California Irvine (UCI)
Irvine, California, 92617, United States
-
University of California Los Angeles
Westwood, Los Angeles, California, 90024, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45229, United States
-
University of Colorado Hospital (UCH) Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.